Who is sponsoring NCT03438500?

NCT03438500 is sponsored by Storz Medical AG.

What drugs are being tested in NCT03438500?

Interventions in NCT03438500: Cardiac Extracorporeal Shockwave Therapy (Modulith SLC).

What condition does NCT03438500 study?

NCT03438500 studies Refractory Angina Pectoris, Ischemic Heart Disease, Coronary Artery Disease.

Is NCT03438500 still recruiting?

NCT03438500 is currently withdrawn. Last updated 31 October 2022.

Last reviewed 2022-10-31 · How we verify

NCT03438500

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

Withdrawn NA Last updated 31 October 2022

What this trial tests

NA trial testing Cardiac Extracorporeal Shockwave Therapy (Modulith SLC) in Refractory Angina Pectoris. Withdrawn.

Timeline

1 September 2022

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Storz Medical AG
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 September 2022
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across Germany

Drugs / interventions tested

Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)

Conditions studied

Refractory Angina Pectoris — all drugs for Refractory Angina Pectoris →
Ischemic Heart Disease — all drugs for Ischemic Heart Disease →
Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Storz Medical AG — full company profile →

Who can join

18 and older, any sex, with Refractory Angina Pectoris or Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the epicardial coronary arteries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Refractory Angina Pectoris

Currently open trials in the same condition.

NCT05711849 — Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina · Phase 2 · recruiting

Other Storz Medical AG trials

Trials by the same sponsor.

NCT04333511 — Brain Stimulation for Patients With Parkinson Disease · NA · completed
NCT03770182 — Brain Stimulation for Neurological Patients · NA · completed
NCT04333329 — Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03438500 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Storz Medical AG
Last refreshed: 31 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03438500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing